Gut microbiota in rheumatoid arthritis: mechanistic insights, clinical biomarkers, and translational perspectives
Qi · 2025 · Autoimmunity Reviews
What this paper found
Review of the gut microbiota in rheumatoid arthritis, with diet as an upstream variable: Western diet → dysbiosis → inflammation; Mediterranean and plant-based diets → microbial diversity → immune tolerance. Same dysbiosis mechanism as the AS papers, with an environmental modifier layer the AS papers don't yet emphasise.
Why this is on the map
Adds the diet dimension that AS papers haven't surfaced yet. Worth the parallel.
On the map under these threads
DOI: 10.1016/j.autrev.2025.103912· opens in a new tab. The full paper is on the publisher’s site, not here.
Related papers on the board
Papers sharing one or more threads with this one.
HLA-B27-associated gut microbiota and amino acid perturbations promote ankylosing spondylitis through M1 macrophage activation
Gut Microbes
Shows that HLA-B27, the gene most strongly linked to AS, reshapes which bacteria live in the gut and how the body handles certain amino acids, which in turn activates the inflammatory immune cells driving the disease. Suggests targeting the gut and these metabolic changes could become a real treatment route.
Gut microbiota and ankylosing spondylitis: current insights and future challenges
Microbial Cell
Comprehensive review of how gut bacterial imbalance disrupts the IL-23/IL-17 inflammatory pathway and weakens the intestinal barrier in AS. Identifies the lack of standardised methodology and large cohorts as the bottleneck for translating this into treatments.
Dysbiosis of Gut Microbiota in Ankylosing Spondylitis Patients
Dove Medical Press
Confirms that intestinal dysfunction precedes or amplifies systemic inflammation in AS. Frames gut microbiota as the convergence point where genetic, immune, and microbial factors meet.
Current status and emerging trends in biological therapies for ankylosing spondylitis: a bibliometric analysis (2004–2024)
Medicine (LWW)
Bibliometric analysis of biological therapies for AS over 2004-2024. Confirms three pillars, TNF, IL-17, and JAK inhibitors, and a persistent inadequate response in a meaningful subset of patients across all three classes.